Deucravacitinib
Deucravacitinib is a pharmaceutical drug with 51 clinical trials. Currently 26 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
12
Mid Stage
23
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
57.1%
12 of 21 finished
42.9%
9 ended early
26
trials recruiting
51
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
Clinical Trials (51)
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Deucravacitinib in the Treatment of Cicatricial Alopecias
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 51